Document Detail


Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
MedLine Citation:
PMID:  18273626     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The prognosis of patients with platinum refractory disease is dismal. We present data from heavily pretreated patients to whom the folinic acid, 5-fluorouracil and oxaliplatin (Folfox) regimen was administered. The objectives were to assess response rate and to evaluate the safety profile. METHODS: Patients with recurrent, resistant or refractory pretreated ovarian carcinoma were eligible for oxaliplatin (85 mg/m(2)) and leucovorin (200 mg/m(2)), both given as a 2-h infusion on day 1, followed by a 48-h infusion of 5FU 2,600 mg/m(2) every 2 weeks. RESULTS: Fourteen patients were treated. Median age: 56 years (49-70). Median number of previous chemotherapy regimens: 5 (3-10) and previous platinum-based regimens: 2 (1-3). Median chemotherapy-free interval (interval since the completion of the last-line chemotherapy before the administration of the Folfox regimen): 9.5 weeks (1-39). Median number of administered cycles of Folfox/patient: 8 (2-11 cycles). Two (14.5%) patients had a disease complete response, 2 (14.5%)-partial response, 4 (29%)-stable disease and 6 (43%)-progressive disease. Four (29%) patients had a CA-125 complete response, 2 (14.5%)-CA-125 partial response, 5 (35.5%)-stable CA-125 levels and 3 (21%)-progressive CA-125 levels. There were no grade 4 adverse events or deaths due to the treatment. No dose modifications were required due to toxicity. CONCLUSIONS: Folfox seems to be a valuable option for heavily pre-treated patients with ovarian cancer, with an overall response rate, according to RECIST criteria, of 29% and disease stabilization in an additional 29% of patients, with a manageable toxicity profile. These results support further assessment of Folfox as salvage treatment for patients with carcinoma of the ovary or fallopian tube.
Authors:
Daniela D Rosa; Ahmad Awada; Max S Mano; Jean Selleslags; Fabienne Lebrun; Thierry Gil; Martine J Piccart; Véronique D'Hondt
Related Documents :
12469146 - Multicenter phase ii study of fractionated bimonthly oxaliplatin with leucovorin and 5-...
18613376 - A phase i trial of cpt-11 and s-1 combination chemotherapy in patients with metastatic ...
17559146 - Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (irox) : intergrou...
12853356 - Multicenter phase ii trial evaluating a three-weekly schedule of irinotecan plus raltit...
2418166 - Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (p...
22868246 - State-of-the-art management of renal cell carcinoma.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2008-02-14
Journal Detail:
Title:  Archives of gynecology and obstetrics     Volume:  278     ISSN:  0932-0067     ISO Abbreviation:  Arch. Gynecol. Obstet.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-09-08     Completed Date:  2009-02-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710213     Medline TA:  Arch Gynecol Obstet     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  457-62     Citation Subset:  IM    
Affiliation:
Department of Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. dornellesrosa@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents / administration & dosage,  adverse effects
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Carcinoma / drug therapy*,  pathology
Cohort Studies
Disease-Free Survival
Fallopian Tube Neoplasms / drug therapy*,  pathology
Female
Fluorouracil / adverse effects
Humans
Leucovorin / adverse effects
Middle Aged
Neoplasm Staging
Organoplatinum Compounds / administration & dosage,  adverse effects
Ovarian Neoplasms / drug therapy*,  pathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Folfox protocol; 0/Organoplatinum Compounds; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 63121-00-6/oxaliplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pregnancy and tuberculosis: to assess tuberculosis cases in pregnancy in a developing region retrosp...
Next Document:  Twin pregnancy with a complete hydatidiform mole and surviving co-existent fetus.